CIMA laboratories.. Called many times last week, and a favorite in the sector, should be reporting January 25, has made substantial gains recently and a good earnings report is expected We waited for a short play to reverse to the upside and we got it last week. Friday only confirmed the play.
Friday January 12, 1:40 pm Eastern Time
CIMA says FDA OK's new form of depression medication
EDEN PRAIRIE, Minn., Jan 12 (Reuters) - Pharmaceutical developer CIMA Labs Inc. (NasdaqNM:CIMA - news) on Friday said the U.S. Food and Drug Administration approved Remeron SolTab, an orally disintegrating tablet to treat depression.
The company said Remeron SolTab, the first orally disintegrating antidepressant approved by the agency, is a different version of Remeron, which has been commercially available in the United States since 1996.
CIMA developed Remeron SolTab for Organon, an affiliate of Dutch chemical group Akzo Nobel NV .
Unlike other antidepressant tablets, which must be swallowed whole, Remeron SolTab dissolves on the tongue within 30 seconds. Organon said it can be swallowed with or without water, chewed or allowed to disintegrate.
CIMA, which is Organon's exclusive supplier of Remeron SolTab, said it expects to begin distributing the tablets in the United States in the first quarter and in some European countries in the second quarter.
CIMA shares were up $5, or 10 percent, at $54 in afternoon trade on the Nasdaq |
